95 results
424B3
CLRB
Cellectar Biosciences Inc
30 Oct 23
Prospectus supplement
7:05pm
, terrorist attacks, natural disasters, public health crises, including the occurrence of a contagious disease or illness such as the COVID-19 pandemic, cyber
8-K
EX-99.1
CLRB
Cellectar Biosciences Inc
14 Aug 23
Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update
8:45am
as to such future outcomes including our expectations of the impact of the COVID-19 pandemic. Drug discovery and development involve a high degree of risk. Factors
8-K
EX-99.1
3fv86chjks jz
13 Jun 23
Cellectar Provides a Research and Development Program Summary
4:30pm
8-K
EX-99.1
o6tjgg
4 May 23
Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
8:45am
424B3
0bxhy32
5 Dec 22
Prospectus supplement
7:04am
8-K
EX-3.1
l9vrhlwo4i jn
2 Dec 22
Entry into a Material Definitive Agreement
5:23pm
8-K
EX-99.1
ufhow7s
3 Nov 22
Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update
8:40am
8-K
EX-99.2
9evrcjue3yoj3x45b78v
25 Oct 22
Entry into a Material Definitive Agreement
5:03pm
8-K
EX-99.1
y3qbv1o y6
25 Oct 22
Entry into a Material Definitive Agreement
5:03pm
424B5
tl197
24 Oct 22
Prospectus supplement for primary offering
4:36pm
8-K
EX-99.1
qll1p2
22 Sep 22
Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors
8:45am
8-K
EX-99.1
6pudegxdgtimro18cq
13 Sep 22
Other Events
8:45am